Entresto Facing Pressure From Diabetes Drugs

 
• By Lucie Ellis-Taitt
  
Pressure
SGLT2 inhibitors, already approved for diabetes, could soon disrupt Novartis's Entresto plans in CHF • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Cardiovascular

More from Therapy Areas